Robocath goes to the OR

Robocath successfully carried out Europe’s first remote robotic-assisted coronary angioplasty.

"Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announced January 13 the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in France - spanning 75 miles (120 km) between the two locations. The procedure is the first of its kind in Europe; it was completed with R-One™, Robocath’s first commercial robotic-assisted platform. This unprecedented achievement opens the door to new options for patients who live in remote areas and require swift treatment to successfully treat cardiovascular diseases.  The procedure was carried out on an animal model on December 8, 2020. Consistent communication between Prof. Sabatier - operating in the Caen University Hospital, and Prof. Durand - based at the Medical Training Center in Rouen, was secured using a variety of tools. 

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer thanks to reliable technologies, while complementing manual interventions. R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One is designed to operate with precision and perform specific movements, creating better interventional conditions. Thanks to its open architecture, R-One is compatible with market-leading devices and cath labs. In a prospective, randomized, controlled pre-clinical trial, R-One demonstrated safety and efficacy as it achieved 100% technical procedure success and no MACE (major adverse cardiovascular events). R-One received the CE marking in February 2019 and started its clinical application in September 2019. Currently R-One is available in Europe and Africa. Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen, France, Robocath has more than 40 employees."

Source: Robocath